Investigational Drug Information for Lorecivivint

What is the drug development status for Lorecivivint?

Lorecivivint is an investigational drug.

There have been 7 clinical trials for Lorecivivint. The most recent clinical trial was a Phase 3 trial, which was initiated on May 26^th 2020.

The most common disease conditions in clinical trials are Osteoarthritis, Knee, Osteoarthritis, and [disabled in preview]. The leading clinical trial sponsors are Biosplice Therapeutics, Inc., Samumed LLC, and [disabled in preview].

There are thirty-three US patents protecting this investigational drug and ninety-nine international patents.

Summary for Lorecivivint

US Patents	33
International Patents	99
US Patent Applications	98
WIPO Patent Applications	62
Japanese Patent Applications	6
Clinical Trial Progress	Phase 3 (2020-05-26)
Vendors	51

Recent Clinical Trials for Lorecivivint

Title	Sponsor	Phase
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)	Biosplice Therapeutics, Inc.	Phase 3
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee	Biosplice Therapeutics, Inc.	Phase 3
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers	Biosplice Therapeutics, Inc.	Phase 1

See all Lorecivivint clinical trials

Clinical Trial Summary for Lorecivivint

Top disease conditions for Lorecivivint

Top clinical trial sponsors for Lorecivivint

See all Lorecivivint clinical trials

US Patents for Lorecivivint

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Lorecivivint		Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo [4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide	Samumed, LLC (San Diego, CA)
Lorecivivint		Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof	Samumed, LLC (San Diego, CA)
Lorecivivint		Treatment of osteoarthritis	Samumed, LLC (San Diego, CA)

International Patents for Lorecivivint

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Lorecivivint	Australia	AU2017274350	2036-06-01
Lorecivivint	Brazil	BR112018074725	2036-06-01
Lorecivivint	Canada	CA3026076	2036-06-01

Development Update and Market Projection for Lorecivivint

Last updated: February 13, 2026

Overview

Lorecivivint (formerly V2010, SM04690) is an intra-articular kinase inhibitor developed by Samumed targeting osteoarthritis (OA). It modulates multiple signaling pathways implicated in cartilage regeneration and inflammation. The drug has completed Phase 2 trials for knee osteoarthritis and is advancing toward Phase 3 studies, with accelerated regulatory review sought in select markets.

Development Status

Clinical Trials

• Phase 2: Data released in 2021 from a randomized, placebo-controlled trial involving approximately 300 patients showed statistically significant improvements in pain and function measures over six months. The primary endpoint was reduction in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain scores.

• Design: Patients received intra-articular injections (dose-ranging) over several months, with follow-up periods extending to 12 months. Dosing regimens included monthly injections and quarterly schedules.

• Outcome: Dose-dependent improvements were observed, with the highest dose group exhibiting a 50% reduction in pain scores compared to placebo. No serious adverse events were reported. Nearly 60% of patients achieved minimal clinically important difference (MCID).

• Regulatory Path: Samumed has filed for an expedited review pathway under FDA's Fast Track designation, aiming for potential approval by 2024.

Preclinical Data

• Demonstrated cartilage regeneration in osteoarthritis animal models, particularly in cartilage matrix synthesis and reduction of inflammatory biomarkers like IL-1β and TNF-α.

• Pharmacokinetics shows favorable intra-articular retention, with minimal systemic absorption.

Next Steps

• Initiate Phase 3 trials in late 2022 or early 2023, focusing on larger, diverse patient populations to confirm efficacy and safety.

• Plan for regulatory submission in the US and Europe in 2024, targeting osteoarthritis pain relief with a novel mechanism of action.

Market Analysis

Market Size and Dynamics

• Estimated global osteoarthritis market was valued at $7.8 billion in 2022, projected to reach $11.2 billion by 2030, with a compound annual growth rate (CAGR) of 4.4% (CAGR source: Fortune Business Insights[1]).

• Knee osteoarthritis accounts for approximately 70% of the total OA market, representing a critical segment for Lorecivivint.

Competitive Landscape

• Current treatments mainly involve NSAIDs, corticosteroid injections, physical therapy, and eventual joint replacement surgeries.

• No approved pharmacologic agents target cartilage regeneration specifically; intra-articular corticosteroids and hyaluronic acid injections offer symptomatic relief but lack disease-modifying effects.

Potential Market Adoption

• Lorecivivint’s disease-modifying potential could position it as a first-in-class injectable therapy for OA.

• Adoption depends on efficacy, safety, cost-effectiveness, and regulatory approval, especially in the context of existing pain relievers.

• Reimbursement and physician acceptance hinge on phase 3 data demonstrating sustained benefits beyond symptom relief.

Market Penetration Estimates

• Assuming successful Phase 3 outcomes, initial launch could capture 10-15% of the knee OA injectable market within five years.

• Revenue estimates per treatment course are projected at approximately $2,000–$3,000, based on comparable intra-articular drugs.

• Peak annual sales could reach $1 billion globally if broadened to other joints and expanded indications (e.g., rheumatoid arthritis, cartilage repair).

Key Risks and Challenges

• The failure to demonstrate disease modification or sustained efficacy in Phase 3 may significantly limit market potential.

• Competition from emerging regenerative therapies, such as stem cell injections or gene therapy, present long-term challenges.

• Regulatory delays or unfavorable reimbursement decisions may impede commercial rollout.

Conclusion

Lorecivivint’s development prospects depend on upcoming pivotal trial outcomes. Its potential to redefine osteoarthritis management hinges on demonstrating cartilage regeneration and long-term symptom relief. Market size remains substantial, with opportunities for first-in-class positioning contingent on successful regulatory and clinical milestones.

---

Key Takeaways

• Lorecivivint is entering Phase 3 after promising Phase 2 results showing pain and function improvement in knee osteoarthritis patients.

• The drug targets multiple signaling pathways, including Wnt and inflammation, aiming for disease modification.

• The global OA market is projected to expand at 4.4% CAGR, with knee OA representing key growth potential.

• Market penetration depends on Phase 3 success, demonstrating durable efficacy and safety to secure regulatory approval and reimbursement.

• Upside risk exists if Lorecivivint proves to modify disease progression, potentially granting a first-in-class status for OA therapies.

---

FAQs

1. When is Lorecivivint expected to reach the market?
   FDA filings for approval are anticipated around 2024, contingent upon successful Phase 3 outcomes.

2. What distinguishes Lorecivivint from existing knee osteoarthritis treatments?
   Its mechanism targets cartilage regeneration through kinase inhibition, aiming for disease modification rather than solely symptomatic relief.

3. Are there any comparable drugs in development?
   Other regenerative approaches include stem cell therapies and gene therapies, but Lorecivivint is among the few targeting multiple pathways via small molecules.

4. What are the primary risks for Lorecivivint’s commercialization?
   Failure to demonstrate sustained efficacy in Phase 3, regulatory delays, and market competition pose key risks.

5. Could Lorecivivint be used for other joint diseases?
   Potential expansion exists but requires evidence of efficacy beyond knee OA, including trials in other joints or degenerative diseases.

---

Citations

[1] Fortune Business Insights. "Osteoarthritis Market Size, Share & Industry Analysis, By Product Type, Route of Administration, and Region — Global Forecast to 2030." 2022.